Enrollment in both trials has significantly outpaced the company’s expectations. As a result its clinical research organizations are still in the process of allocating the resources required to manage and complete the site closeout and data management activities.
“In iloperidone, we look forward to providing schizophrenia patients and their physicians a compound with a differentiated safety profile and unique pharmacogenetic tools for identifying optimal iloperidone responders. We believe that VEC-162 offers a novel way of treating insomnia, in particular those patients with circadian rhythm disorders,” said Mihael Polymeropoulos president and CEO of Vanda.
The company has said they expect to report top-line results for the iloperidone trials in January, 2007.